Can Roche’s Tecentriq leapfrog rival meds in lung cancer? Jury’s still out

On Thursday, Roche unveiled positive results from its first-line lung-cancer combo trial—but those results raised more questions than they provided answers.
Read the full story: FiercePharma: Pharma